Etiology of Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD) in Japan

GlaxoSmithKline70 enrolled

Overview

The purpose of this prospective, epidemiological, cohort study is to evaluate the lung microbiome in stable-state chronic obstructive pulmonary disease (COPD) in Japanese participants

Study Type

OBSERVATIONAL

Enrollment

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

Prospective observational cohort studyOTHER

Prospective observational cohort study

Eligibility

Sex: ALLMin age: 40 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Participants must be able and willing to comply with the requirements of the protocol. * Participant must be aged greater than or equal to (\>=)40 years to to less than or equal to (\<=)80 years at the time of signing the informed consent form (ICF). * Participants must have a record of a clinical diagnosis of COPD, ACOS or CB. * Participants must have moderate to severe airflow limitation based on spirometry: FEV1 percent predicted normal \>=30 to \<=80 percent (%) and post-bronchodilator FEV1/forced vital capacity (FVC) ratio \<0.7. * Participants must be symptomatic at Screening, defined as having a CAT score \>=10. * Participants must have a documented history of at least 1 LRTI treated with antibiotics and/or oral/systemic corticosteroids. * Participants must be current or former tobacco (cigarette) smokers with a smoking history of \>=10 pack-years. * Participants may be male or female. For female participants: A female participant is eligible to participate if she is not pregnant or breastfeeding. Women of non-childbearing potential can also participate. A woman of childbearing potential must have had a highly sensitive negative urine pregnancy test. * Participants should be able to provide a spontaneous or induced sputum sample of \>=0.2 grams (g) at the Screening Visit. Exclusion Criteria: * Participants with a diagnosed respiratory disorder other than COPD, ACOS or CB. * Participants with a diagnosis of alpha-1 antitrypsin deficiency as the underlying cause of COPD. * Participants who have received antibiotics within 1 month of Screening or have received antibiotics for more than 30 days within 90 days prior to Screening; Except for those who have received and are currently receiving long-term treatment with low-dose macrolide: erythromycin \<=600 milligrams (mg) per (/) day or clarithromycin \<=200 mg/day. * Participants who have received systemic corticosteroids (oral/intravenous/intramuscular) for more than 14 consecutive days within 90 days prior to giving informed consent. * Participants who are unable to use or to comply with daily completion of the eDiary.

Locations (13)

GSK Investigational Site

Fukuoka, Japan

GSK Investigational Site

Fukuoka, Japan

GSK Investigational Site

Fukuoka, Japan

Outcomes

Primary Outcomes

Number of participants with first evaluable moderate or severe AECOPD that have infectious or non-infectious etiology

Time frame: Up to Month 12

Microbiome composition of sputum in stable-state COPD as measured by bacterial ribosomal ribonucleic acid (rRNA) sequencing

Time frame: Baseline (Screening visit or Month 0)

Secondary Outcomes

Number of all-cause moderate and severe AECOPD per participants

Time frame: Up to Month 12

Microbiome composition of sputum in stable-state COPD as measured by bacterial rRNA sequencing

Time frame: Baseline (Screening visit or Month 0)

Microbiome composition of sputum during participant's first evaluable moderate or severe AECOPD

Time frame: Up to Month 12

Number of participants with first evaluable sputum samples that are positive for potentially pathogenic viruses (overall and by species) and bacteria in stable state COPD as measured by bacterial culture or quantitative polymerase chain reaction (qPCR)

Time frame: Baseline (Screening visit or Month 0)

Number of participants with first evaluable sputum samples that are positive for potentially pathogenic viruses (overall and by species) and bacteria during moderate or severe AECOPD as measured by bacterial culture or qPCR

Time frame: Baseline (Screening visit or Month 0)

Number of EXACT events per participant over the course of 12 months

An EXACT event is defined as an increase in EXACT score more than or equal to 12 points for 2 days or more than or equal to 9 points for 3 days, above the participant's mean Baseline score. Severity is indicated by the worst (i.e., highest) EXACT total score during the course of the event.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

GSK Investigational Site

Fukushima, Japan

GSK Investigational Site

Hiroshima, Japan

GSK Investigational Site

Mie, Japan

GSK Investigational Site

Nagasaki, Japan

GSK Investigational Site

Niigata, Japan

GSK Investigational Site

Osaka, Japan

GSK Investigational Site

Osaka, Japan

...and 3 more locations

Time frame: Up to Month 12

Number of AECOPD events

Time frame: Up to Month 12

Severity of AECOPD according to healthcare utilization

Time frame: Up to Month 12

Severity of EXACT events according to EXACT total score

Time frame: Up to Month 12

Duration of AECOPD

Time frame: Up to Month 12

Duration of EXACT events

Time frame: Up to Month 12

Mean change in CAT score between stable-state COPD and participants' first evaluable moderate or severe AECOPD

The CAT is a 8-item, participant-completed instrument that covers symptoms such as cough, phlegm, chest tightness and breathlessness, and disease impacts including physical activity, confidence, sleep and energy. Participants will be asked to score each item on a scale ranging from 0 (no symptom or impact at all) to 5 (maximal symptom or impact).

Time frame: Baseline (Screening visit or Month 0) and up to Month 12

Mean change in CAT score over the course of 1 year

Time frame: Baseline (Screening visit or Month 0) and up to Month 12

Mean change in EXACT score

EXACT is a validated, self-administered, 14-item daily diary that assesses 11 respiratory symptoms and 3 additional symptoms, which together characterize COPD exacerbations. The EXACT total score will range from 0 to 100, with higher scores indicating a more severe condition.

Time frame: Baseline(Screening visit or Month 0) and up to Month 12

Mean change in E-RS COPD total and subscale scores between stable-state COPD and participants' first evaluable moderate or severe AECOPD

The E-RS: COPD comprises 11 of the 14 items of the parent EXACT that are specifically related to respiratory symptoms and will be completed using the eDiary. The RS-Total score is computed by taking the sum of the items comprising the instrument, with scores ranging from 0 to 40, with higher scores indicating more severe respiratory symptoms.

Time frame: Baseline (Screening visit or Month 0) and up to Month 12

Mean change in E-RS: COPD total and subscale scores over the course of 1 year

Time frame: Baseline (Screening visit or Month 0) and up to Month 12

Mean change in Forced expiratory volume in 1 second (FEV1) between stable-state COPD, during participants' first evaluable moderate or severe AECOPD

Time frame: Baseline (Screening visit or Month 0) and up to month 12

Mean rate of AECOPD related healthcare resource utilization per participant

Time frame: Up to Month 12

Mean rate of non-AECOPD related healthcare resource utilization per participant

Time frame: Up to Month 12

Annual rate of AECOPD related healthcare resource utilization per participant

Time frame: Up to Month 12

Annual rate of non-AECOPD related healthcare resource utilization per participant

Time frame: Up to Month 12